Strategies to optimize drug half-life in lead candidate identification

References

• Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):457–486.
   PubMed Web of Science ®Google Scholar
• Varma MV, Ambler CM, Ullah M, et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab. 2010;11(9):730–742.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keserü GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13:105–121.
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58(1):388–396.
   PubMed Web of Science ®Google Scholar
• Paes AHP, Barker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512–1517.
   PubMed Web of Science ®Google Scholar
• Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev. 1971;71(6):525–616.
   Web of Science ®Google Scholar
• Broccatelli F, Aliagas I, Zheng H. Why decreasing lipophilicity alone is often not a reliable strategy for extending IV half-life. ACS Med Chem Lett. 2018;9(6):522–527.
   PubMed Web of Science ®Google Scholar
• Gunaydin H, Altman MD, Ellis JM, et al. Strategy for extending half-life in drug design and its significance. ACS Med Chem Lett. 2018;9(6):528–533.
   PubMed Web of Science ®Google Scholar
• Smith DA, Beaumont K, Maurer TS, et al. Relevance of half-life in drug design. J Med Chem. 2018;61(10):4273–4282.
   PubMed Web of Science ®Google Scholar
• Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. In Pharm Res. 2008;25(12):2869–2877.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929–939.
   PubMed Web of Science ®Google Scholar
• Liu X, Wright M, Hop CECA. Rational use of plasma protein and tissue binding data in drug design. J Med Chem. 2014;57(20):8238–8246.
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “Well-stirred” model and a “Parallel tube” model. influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625–653.
   PubMedGoogle Scholar
• McGinnity DF, Collington J, Austin RP, et al. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab. 2007;8(5):463–479.
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36(7):1385–1405.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–121.
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–249.
   PubMed Web of Science ®Google Scholar
• Leeson PD, Empfield JR. Reducing the risk of drug attrition associated with physicochemical properties. Ann Rep Med Chem. 2010;45:393–407.
   Web of Science ®Google Scholar
• Young RJ, Green DVS, Luscombe CN, et al. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today. 2011;16(1):822–830.
   PubMedGoogle Scholar
• Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower LogD limits based on permeability. Bioorg Med Chem Lett. 2009;19(10):2844–2851.
   PubMed Web of Science ®Google Scholar
• Johnson TW, Dress KR, Edwards M. Using the golden triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett. 2009;19(19):5560–5564.
   PubMed Web of Science ®Google Scholar
• Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem. 2008;51(4):817–834.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Kanaoka M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. J Pharm Sci. 2004;93(6):1480–1494.
   PubMed Web of Science ®Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6(11):881–890.
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett. 2008;18(17):4872–4875.
   PubMed Web of Science ®Google Scholar
• Luker T, Alcaraz L, Chohan KK, et al. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. Bioorg Med Chem Lett. 2011;21:5673–5679.
   PubMed Web of Science ®Google Scholar
• Ringel M, Tollman P, Hersch G, et al. Does size matter in R&D productivity? If not, what does? Nat Rev Drug Discov. 2013;12:901–902.
   PubMed Web of Science ®Google Scholar
• Nassar AEF, Kamel AM, Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov Today. 2013;9(23):1020–1028.
   Google Scholar
• Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine (P07.210). Neurology. 2013;80(Suppl 7):P07.210.
   Web of Science ®Google Scholar
• Benet L, Broccatelli F, Oprea T. BDDCS applied to over 900 drugs. Aaps J. 2011;13(4):519–547.
   PubMed Web of Science ®Google Scholar
• Milletti F, Storchi L, Sforna G, et al. New and original PKa prediction method using grid molecular interaction fields. J Chem Inf Model. 2007;47(6):2172–2181.
   PubMed Web of Science ®Google Scholar
• Chan R, De Bruyn T, Wright M, et al. Comparing mechanistic and preclinical predictions of volume of distribution on a large set of drugs. Pharm Res. 2018;35(4):87.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918–933.
   PubMed Web of Science ®Google Scholar
• Fischer H, Atzpodien EA, Csato M, et al. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. J Med Chem. 2012;55(1):126–139.
   PubMed Web of Science ®Google Scholar
• Broccatelli F, Salphati L, Plise E, et al. Predicting passive permeability of drug-like molecules from chemical structure: where are we? Mol Pharm. 2013;58(1):388–396.
   Google Scholar
• Broccatelli F, Mannhold R, Moriconi A, et al. QSAR modeling and data mining link torsades de pointes risk to the interplay of extent of metabolism, active transport, and HERG liability. Mol Pharm. 2016;13(12):4199–4208.
   PubMedGoogle Scholar
• Cruciani G, Baroni M, Benedetti P, et al. Exposition and reactivity optimization to predict sites of metabolism in chemicals. Drug Discov Today Technol. 2013;10(1):e155–e165.
   PubMedGoogle Scholar
• Ahlström MM, Ridderström M, Zamora I. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. J Med Chem. 2007;50(22):5382–5391.
   PubMed Web of Science ®Google Scholar
• Woodward HL, Innocenti P, Cheung KJ, et al. Introduction of a methyl group curbs metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) inhibitors and enables the discovery of the phase 1 clinical candidate N2-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine (BOS172722). J Med Chem. 2018;61(18):8226–8240.
   PubMed Web of Science ®Google Scholar
• Pähler A, Brink A. Software aided approaches to structure-based metabolite identification in drug discovery and development. Drug Discov Today Technol. 2013;10(1):207–217.
   PubMedGoogle Scholar
• Lombardo F, Desai PV, Arimoto R, et al. In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international consortium for innovation through quality in pharmaceutical development. J Med Chem. 2017;60(22):9097–9113.
   PubMed Web of Science ®Google Scholar
• Kramer C, Ting A, Zheng H, et al. Learning medicinal chemistry absorption, distribution, metabolism, excretion, and toxicity (admet) rules from cross-company Matched Molecular Pairs Analysis (MMPA). J Med Chem. 2013;58(1):388–396.
   Google Scholar
• Aliagas I, Gobbi A, Heffron T, et al. A probabilistic method to report predictions from a human liver microsomes stability qsar model: a practical tool for drug discovery. J Comput Aided Mol Des. 2018;61(8):3277–3292.
   Google Scholar
• Stepan AF, Kauffman GW, Keefer CE, et al. Evaluating the differences in cycloalkyl ether metabolism using the design parameter “Lipophsilic metabolism efficiency” (LipMetE) and a matched molecular Pairs analysis. J Med Chem. 2013;56(17):6985–6990.
   PubMed Web of Science ®Google Scholar
• Schenkel LB, Olivieri PR, Boezio AA, et al. Optimization of a novel quinazolinone-based series of transient receptor potential A1 (TRPA1) antagonists demonstrating potent in vivo activity. J Med Chem. 2016;59:2794–2809.
   PubMed Web of Science ®Google Scholar
• Di L, Obach RS. Addressing the challenges of low clearance in drug research. Aaps J. 2015;17(2):352–357.
   PubMed Web of Science ®Google Scholar
• Varma MVS, Chang G, Lai Y, et al. Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab Dispos. 2012;40(8):1527–1537.
   PubMed Web of Science ®Google Scholar
• Piroli RJ, Passananti GT, Shively CA, et al. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin Pharmacol Ther. 1981;30(6):810–816.
   PubMed Web of Science ®Google Scholar